Menu
The Goodman Institute Health Blog
  • Home
  • Authors
    • Devon Herrick, Ph.D.
    • John C. Goodman
  • Popular Topics
    • Artificial Intelligence and Healthcare
    • Consumer-Driven Health Care
      • Affordable Care Act
      • Cost of Healthcare
      • COVID-19 and Public Health
      • Doctors & Hospitals
      • Public Insurance
      • Policy & Legislation
    • Direct Primary Care
    • Health Economics & Costs
      • Drug Prices & Regulations
      • Health Insurance
      • Health Reform
    • Medical Tourism
    • Telemedicine
    • Medicare
      • Single-Payer/Medicare-for-All
  • Goodman Institute
  • Contact
The Goodman Institute Health Blog

Category: Drug Prices & Regulations

Friday Links

Posted on December 2, 2022 by John C. Goodman
  • Is Obamacare’s requirement that preventive services be provided with no patient cost sharing unconstitutional?
  • New York Times: Older doctors should be given competency exams. One-third of US doctors are 60 years of age or older.
  • Have nurse’s license, will travel: The average weekly rate for travel nurses is $3,080 — about $700 less than it was a year ago. 
  • Since its founding in 1973, the DEA has intercepted a fraction of one percent of illicit drug trades. 
  • Physicians want to protect their guild from proposals to let nurses do what they are trained and qualified to do.
  • Cato paper: “Medical decisionmaking is increasingly under the purview of law enforcement. Practitioners and patients alike are often prejudged as criminals.”
+

FDA Approves Fecal Transplants as though it were a Drug

Posted on December 1, 2022 by Devon Herrick

Clostridium difficile infections  (CDI) are difficult to treat and can be deadly. CDI is an infection of the gut when the gut bacteria are thrown out of balance and populated with Clostridium difficile rather than a healthy biome. The standard treatment is antibiotics, which can also wreck beneficial gut biome.  CDI often is recurrent, coming back time and time again.

+

Thursday Links

Posted on December 1, 2022 by John C. Goodman
  • The social upside of dangerous motorcycle riding.
  • Does anyone remember Climategate?
  • Harvard study: Medicare could have saved $3.6 billion in a single year if it had bought generic drugs from Mark Cuban’s online pharmacy.  (DMN)
  • Health Affairs study: no evidence that the child tax credit had an effect on the wellbeing and mental health of parents.
+

New Alzheimer’s Drug May be a Breakthrough! Or a Dud!

Posted on November 30, 2022November 30, 2022 by Devon Herrick

In June of 2021 the Alzheimer’s drug, Aduhelm, was approved by the U.S. Food and Drug Administration (FDA). Aduhelm is a monoclonal antibody. It targets a specific protein in the brain that is thought to form plaques in the brains of Alzheimer’s patients, causing brain cells to atrophy and die.

+
  • Previous
  • 1
  • …
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184
  • 185
  • …
  • 221
  • Next

For many years, our health care blog was the only free enterprise health policy blog on the internet. Then, when the NCPA closed its doors, the health blog stopped as well.

During this five-year hiatus no one else has come forward to claim the space. So, my colleagues and I have decided to restart the blog in connection with the Goodman Institute. We invite you and others to use this forum to share your views.

John C. Goodman,

Visit www.goodmaninstitute.org

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 40 other subscribers

Popular Topics

©2026 The Goodman Institute Health Blog | Website by Lexicom